

## DAFTAR PUSTAKA

- Aberg J.A., Lacy, C., Amstrong, L., Goldman, M., and Lance, L.L., 2009, *Drug Information Handbook* 17<sup>th</sup> Edition, American Pharmacist Association.
- Akpınar, E., Cerit, C., Talas, A., & Tural, Ü., 2016, Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability, *Clinical Psychopharmacology and Neuroscience*, 14(4), 351–356, <https://doi.org/10.9758/cpn.2016.14.4.351>
- American Psychiatric Association, 2017, *What Is Depression?* Depression, diakses pada <https://www.psychiatry.org/patients-families/depression/what-is-depression>
- Amini H., Aghayan S., Jalili S.A., Akhondzadeh S., Yahyazadeh O., Pakravan-Nejad M., 2005, Comparison of Mirtazapin and Fluoxetine in the Treatment of Major Depressive Disorder: A Double-blind, Randomized Trial, *Journal of Clinical Pharmacy and Therapeutics*, Volume 30, 133-138.
- Ansseau, M., Demyttenaere, K., Heyrman, J., Migeotte, A., Leyman, S., & Mignon, A., 2009, Objective: Remission of depression in primary care. *European Neuropsychopharmacology*, 19(3), 169–176, <https://doi.org/10.1016/j.euroneuro.2008.10.003>
- Baldwin, D. S., Hawley, C. J., Mellors, K., & On behalf of the CN104-070 study group, 2001, A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: Safety, tolerability and efficacy in continuation phase treatment, *Journal of Psychopharmacology*, 15(3), 161–165, <https://doi.org/10.1177/026988110101500303>
- Basu, B., Gangopadhyay, T., Dutta, N., Mandal, B., De, S., & Mondal, S., 2014, A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature, *Current Drug Safety*, 9(1), 56–59, <https://doi.org/10.2174/157488630901140224104651>
- Bathla, M., & Anjum, S., 2020, A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression, *Indian Journal of Pharmacology*, 52(1), 10, [https://doi.org/10.4103/ijp.IJP\\_618\\_18](https://doi.org/10.4103/ijp.IJP_618_18)
- Bathla, M., Anjum, S., Singh, M., Panchal, S., & Singh, G. P., 2018, A 12-week Comparative Prospective Open-label Randomized Controlled Study in Depression Patients Treated with Vilazodone and Escitalopram in a Tertiary Care Hospital in North India, *Indian Journal of Psychological Medicine*, 40(1), 80–85. [https://doi.org/10.4103/IJPSYM.IJPSYM\\_368\\_17](https://doi.org/10.4103/IJPSYM.IJPSYM_368_17)
- Bhowmik D., Kumar K.P.S., Sricastava S., Paswan S., Dutta A.S., 2020, Depression-Symptoms, Causes, Medications and Therapies, *The Pharma Journal*. Vol 1 No. 3 2012, ISSN 2277-7695

- Blum, L., 2009, *Montgomery Asberg Depression Rating Scale (MADRS) – Strokingine*, diakses pada <https://strokengine.ca/en/assessments/montgomery-asberg-depression-rating-scale-madrs/>
- Bondy, B., MD., 2002, Pathophysiology of depression and mechanisms of treatment, *Dialogues in Clinical Neuroscience*, 4(1), 7–20, <https://doi.org/10.31887/DCNS.2002.4.1/bbondy>
- Brody, D. J., Pratt L. A. Hughes J. P., 2018, Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013–2016, *National Center for Health Statistics*, Volume 303, 8.
- Calandra, C., Russo, R. G., & Luca, M., 2012, Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study, *Psychiatr Q*, 83:177–185. <https://doi.org/10.1007/s11126-011-9192-0>
- Chouinard, G., Saxena, B., Belanger, M.-C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Nair, N. P. V., Manchanda, R., Reesal, R., Remick, R., & O'Neill, M. C., 1999, A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder, *Journal of Affective Disorders*, Volume 54. 39–48.
- Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R., 2018, Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis, *The Lancet*, 391(10128), 1357–1366. [https://doi.org/10.1016/S0140-6736\(17\)32802-7](https://doi.org/10.1016/S0140-6736(17)32802-7)
- Culpepper, L., Davidson, J. R. T., Dietrich, A. J., Goodman, W. K., Kroenke, K., & Schwenk, T. L., 2004, Suicidality as a Possible Side Effect of Antidepressant Treatment, *Prim Care Companion j Clin Psychiatry* 2004. Volume 6(2)
- Daly, C., 2016, Oral and dental effects of antidepressants. *Aust Prescr*, 2016;39:84, <http://dx.doi.org/10.18773/austprescr.2016.035>
- Davidson, J. R. T., Meoni, P., Haudiquet, V., Cantillon, M., & Hackett, D., 2002, Achieving remission with venlafaxine and fluoxetine in major depression: Its relationship to anxiety symptoms, *Depression and Anxiety*, 16(1), 4–13. <https://doi.org/10.1002/da.10045>
- Eugene, A. R., 2020, Association of sleep among 30 antidepressants: A population-wide adverse drug reaction study, 2004–2019, *PeerJ*, 8, e8748, <https://doi.org/10.7717/peerj.8748>
- Fagiolini, A., Albert, U., Ferrando, L., Herman, E., Muntean, C., Pálová, E., Cattaneo, A., Comandini, A., Di Dato, G., Di Loreto, G., Olivieri, L., Salvatori, E., Tongiani, S., & Kasper, S., 2020, A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major

- depressive disorder: *International Clinical Psychopharmacology*, 35(3), 137–146, <https://doi.org/10.1097/YIC.0000000000000304>
- Fasipe, O., 2018, Neuropharmacological classification of antidepressant agents based on their mechanisms of action, *Archives of Medicine and Health Sciences*, 6(1), 81, [https://doi.org/10.4103/amhs.amhs\\_7\\_18](https://doi.org/10.4103/amhs.amhs_7_18)
- Feighner, J. P., Jacobs, R. S., Jackson, R. E., Merideth, C. H., & O'Meara, P. D., 1983, A Double-Blind Comparative Trial With Mianserin And Amitriptyline In Outpatients With Major Depressive Disorders, *J. Clin. Pharmacol*, Volume 15, 2278-2378.
- Ferguson, J. M., 2001, SSRI Antidepressant Medications: Adverse Effects and Tolerability, *Primary Care Companion J Clin Psychiatry*. Volume 3. 22-27
- Ferrari, R., 2015, Writing narrative style literature reviews, *Medical Writing*, 24(4), 230–235, <https://doi.org/10.1179/2047480615Z.00000000000329>
- Hamilton, M., 1960, A RATING SCALE FOR DEPRESSION, *J. Neurol. Neurosurg. Psychiat.*, 1960, Volume 23, 56.
- He, Y., Kang, R., Yan, Y., Li, Z., Wu, Y., Guo, X., Liang, Z., & Jiang, J., 2015, Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: A double-blind, randomized, clinical trial, *Neuropsychiatric Disease and Treatment*, 1307, <https://doi.org/10.2147/NDT.S85711>
- Hewett, Chrzanowski, W., Schmitz, M., Savelle, A., Milanova, V., Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J., 2009, Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR, *Journal of Psychopharmacology*, Volume 23, 531-538. <https://doi.org/10.1177/0269881108089602>
- Hewett, Gee, M. D., Krishen, A., Wunderlich, H.-P., Clus, A. L., Evoniuk, G., & Modell, J. G., 2010, Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR, *Journal of Psychopharmacology*, 8. volume 24(8). 1209-1216. <https://doi.org/10.1177/0269881109106953>
- Hudson, J. I., Perahia, D. G., Gilaberte, I., Wang, F., Watkin, J. G., & Detke, M. J., 2007, Duloxetine in the treatment of major depressive disorder: An open-label study, *BMC Psychiatry*, 11. Volume 7. 43. <https://doi.org/10.1186/1471-244X-7-43>
- Jiang, K., Li, L., Xueyi, W., Fang, M., Shi, J., Cao, Q., He, J., Wang, J., Tan, W., & Hu, C., 2017, Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: A 24-week, open-label, prospective study in Chinese population, *Neuropsychiatric Disease and Treatment*, Volume 13, 515–526, <https://doi.org/10.2147/NDT.S120190>
- Kang, E.-H., Lee, I.-S., Chung, S.-K., Lee, S.-Y., Kim, E.-J., Hong, J.-P., Oh, K.-S., Woo, J.-M., Kim, S., Park, J.-E., & Yu, B.-H., 2009, Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major

- depressive disorder: A randomized, open-labeled trial, *Psychiatry Research*, Volume 169. 118-123. <https://doi.org/10.1016/j.psychres.2008.06.021>
- Kasper, S., Baldwin, D. S., Larsson Lönn, S., & Boulenger, J.-P., 2009, Superiority of escitalopram to paroxetine in the treatment of depression, *European Neuropsychopharmacology*, 19(4), 229–237. <https://doi.org/10.1016/j.euroneuro.2008.12.003>
- Kementerian Kesehatan Republik Indonesia, 2018, *Laporan Nasional RISKESDAS 2018*, Depkes RI, Jakarta. 225-227.
- Kennedy, S. H., Andersen, H. F., & Lam, R. W., 2006, Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis, *J Psychiatry Neurosci*, Volume 31(2). 122-131
- Khan A., Bose A., Alexopoulos G.S., Gommoll C., Li D., Gandhi C., 2007, Double-blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder, *Clin Drug Invest*, Volume 27 (7): 481-492.
- Lam, R. W., Andersen, H. F., & Wade, A. G., 2008, Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials, *International Clinical Psychopharmacology*, 23(4), 181–187. <https://doi.org/10.1097/YIC.0b013e3282ffdedc>
- Lapierre, Y. D., Joffe, R., McKenna, K., Bland, R., Kennedy, S., Ingram, P., Reesal, R., Rickhi, B. G., Beauclair, L., Chouinard, G., & Annable, L., 1997, Moclobemide versus Fluoxetine in the Treatment of Major Depressive Disorder in Adults, *Journal Of Psychiatry*, Volume 22(2), 9.
- Lee, P., Shu, L., Xu, X., Wang, C. Y., Lee, M. S., Liu, C.-Y., Hong, J. P., Ruschel, S., Raskin, J., Colman, S. A., & Harrison, G. A., 2007, Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil: Duloxetine in the treatment of MDD, *Psychiatry and Clinical Neurosciences*, 61(3), 295–307, <https://doi.org/10.1111/j.1440-1819.2007.01666.x>
- Lin H., Hsu Y., Liu C., Chen C., Hsiao M., Liu Y., Shen W.W., Hsiao C., Liu S., Chang L., Tang H., Lai H., Lin P., Lin K., Tsou H., 2013, Comparison of Escitalopram and Paroxetine in the Treatment of Major Depressive Disorder, *Wolters Kluwer Health*, Volume 28. 339-345. <https://doi.org/10.1097/YIC.0b013e32836458e2>
- Mackay, F. R., Dunn, N. R., Martin, R. M., Pearce, G. L., Freemantle, S. N., & Mann, R. D., 1999, Newer antidepressants: A comparison of tolerability in general practice, *British Journal of General Practice*, Volume 49. 892-896.
- Maneeton, B., Maneeton, N., Likhitsathian, S., Woottitluk, P., Wiriyacosol, P., Boonyanaruthee, V., & Srisurapanont, M., 2018, Escitalopram vs duloxetine in acute treatment of major depressive disorder: Meta-analysis and systematic review, *Neuropsychiatric Disease and Treatment*, Volume 14, 1953–1961. <https://doi.org/10.2147/NDT.S152410>

- Mao, P., Gu, X., & Mitchell, P. B., 2006, Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population, *Wiley InterScience*, Volume 25. 46-54. <https://doi.org/10.1002/da.20222>
- McNally, K., 2020, *Library Resource Guides: Literature Review: Traditional or narrative literature reviews*, diakses pada <https://libguides.csu.edu.au/review/Traditional>
- Montejo, A. L., Calama, J., Rico-Villademoros, F., Montejo, L., González-García, N., Pérez, J., & SALSEX Working Study Group, 2019, A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study, *Archives of Sexual Behavior*, 48(3), 923–933, <https://doi.org/10.1007/s10508-018-1365-6>
- Montgomery S.A., Huusom A.K.T., Bothmer J., 2004, A Randomized Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder, *Neuropsychobiology*, 50:57-64. <https://doi.org/10.1159/000078225>
- Montgomery, S., Hansen, T., & Kasper, S., 2011, Efficacy of escitalopram compared to citalopram: A meta-analysis, *The International Journal of Neuropsychopharmacology*, 14(02), 261–268. <https://doi.org/10.1017/S146114571000115X>
- Mowla, A., Dastgheib S.A., Jahromi L.R., 2016, Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial, *Clin Drug Investig*, 36, 539-543. <https://doi.org/10.1007/s40261-016-0399-6>
- Nasso, E. D., Chiesa, A., Serretti, A., Ronchi, D. D., & Mencacci, C., 2011, Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression, *Clin Drug Investig*, Volume 31(6). 385-405.
- Nayer, A. D., Geerts, S., Ruelens, L., Schittecatte, M., Bleeker, E. D., Eeckhoutte, I. V., Evrard, J.-L., Linkowski, P., Fossion, P., Leyman, S., & Mignon, A., 2002, Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. *International Journal of Neuropsychopharmacology*, Volume 5, 115-120. <https://doi.org/10.1017/S1461145702002857>
- Nemeroff, C. B., & Thase, M. E., 2007, A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients, *Journal of Psychiatric Research*, 41(3–4), 351–359, <https://doi.org/10.1016/j.jpsychires.2005.07.009>
- Ou, J.-J., Xun, G.-L., Wu, R.-R., Li, L.-H., Fang, M.-S., Zhang, H.-G., Xie, S.-P., Shi, J.-G., Du, B., Yuan, X.-Q., & Zhao, J.-P., 2011, Efficacy and safety of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, randomized, double-blind, flexible-dose study, *Psychopharmacology*, 213(2–3), 639–646, <https://doi.org/10.1007/s00213-010-1822-y>



- Patel, J., & Marwaha, R., 2021, Akathisia. In *StatPearls*. StatPearls Publishing, diakses pada <http://www.ncbi.nlm.nih.gov/books/NBK519543/>
- Pezella G., Moslinger-Gehmayr R., Contu A., 2001, Treatment of Depression in Patients with Breast Cancer: A Comparison Between Paroxetine and Amitriptyline, *Breast Cancer Research and Treatment*, Volume 70,1.
- PIO Nas, 2021, *Amitriptilin Hidroklorida*, diakses pada <http://pionas.pom.go.id/monografi/amitriptilin-hidroklorida>
- Prasetyaningrum, E., & Advistasari, Y. D., 2016, *Kajian Obat Fluoksetin dan Sertraline Pasien Depresi Berat di Instalasi Rawat Inap RSJD Dr. Amino Godohutomo Provinsi Jawa Tengah Periode Juli-Desember 2016*. ISSN 2528-5912
- Psychiatry & Neurology Resource Center, 2017, *Assessing depression*, diakses pada <https://progress.im/en/content/assessing-depression-0>
- Rapaport M., Emil C., Yvette S., Teri P., Peter H., Louis F., Dianne B., 1996, A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major Depression, *Journal of Clinical Psychopharmacology*, Volume 16, 373-378.
- Ravindran, A. V., Judge, R., Hunter, B. N., Bray, J., Morton, N. H., & The Paroxetine Study Group, 1997, A Double-Blind, Multicenter Study in Primary Care Comparing Paroxetine and Clomipramine in Patients With Depression and Associated Anxiety, *The Journal of Clinical Psychiatry*, 58(3), 112–118, <https://doi.org/10.4088/JCP.v58n0305>
- Reeves, R. R., & Ladner, M. E., 2010, Antidepressant-Induced Suicidality: An Update: Antidepressant-Induced Suicidality. *CNS Neuroscience & Therapeutics*, <https://doi.org/10.1111/j.1755-5949.2010.00160.x>
- Rubino, A., Roskell, N., Tennis, P., Mines, D., Weich, S., & Andrews, E., 2007, Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: Retrospective cohort study, *BMJ*, 334(7587), 242, <https://doi.org/10.1136/bmj.39041.445104.BE>
- Salazar-Fraile, J., Sempere-Verdú, E., Pérez-Hoyos, S., Tabarés-Seisdedos, R., & Gómez-Beneyto, M., 2018, Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care, *Frontiers in Psychiatry*, 9, 416, <https://doi.org/10.3389/fpsy.2018.00416>
- Schneeweiss, S., Patrick, A. R., Solomon, D. H., Mehta, J., Dormuth, C., Miller, M., Lee, J. C., & Wang, P. S., 2010, Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults: A Propensity Score-Adjusted Analysis of 9 Years' Data, *Archives of General Psychiatry*, 67(5), 497, <https://doi.org/10.1001/archgenpsychiatry.2010.39>
- Schulz, P., & Macher, J.-P., 2002, The clinical pharmacology of depressive states, *Dialogues in Clinical Neuroscience*, Volume 4:47-56.
- Scully, C., 2003, Drug effects on salivary glands: Dry mouth: Drug effects on salivary glands: dry mouth. *Oral Diseases*, 9(4), 165–176. <https://doi.org/10.1034/j.1601-0825.2003.03967.x>

- Sharma, B., 2017, Antidepressants: Mechanism of Action, Toxicity and Possible Amelioration, *Journal of Applied Biotechnology & Bioengineering*, 3(5), <https://doi.org/10.15406/jabb.2017.03.00082>
- Sharma, T., Guski, L. S., Freund, N., & Gøtzsche, P. C., 2016, Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. *BMJ*, i65. <https://doi.org/10.1136/bmj.i65>
- Shen, Y., Zhao, Q., Yu, Y., Tan, Y., Zhang, H., Xu, X., Wang, Z., Li, Y., Hu, J., Zhong, J., & Li, H., 2019, Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial, *Journal of Affective Disorders*, 257, 143–149, <https://doi.org/10.1016/j.jad.2019.07.023>
- Shu, L., Sulaiman A.H., Huang Y.S., Leng C.F.S., Crutel V.S., Kim Y.S., 2014, Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50mg or fluoxetine 20–40mg in Asian out-patients with major depressive disorder, *Asian Journal of Psychiatry*, 7. <http://dx.doi.org/10.1016/j.ajp.2013.09.009>
- Sinyor, M., Cheung, C. P., Abraha, H. Y., Lanctôt, K. L., Saleem, M., Liu, C. S., Li, A., Juda, A., Levitt, A. J., Cheung, A. H., & Schaffer, A., 2020, Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review, *Journal of Affective Disorders*, 267, 185–190, <https://doi.org/10.1016/j.jad.2020.02.013>
- Sögaard, J., Lane, R., Latimer, P., Behnke, K., Christiansen, P. E., Nielsen, B., Ravindran, A. V., Reesal, R. T., & Goodwin, D. P., 1999, A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression, *Journal of Psychopharmacology*, 13(4), 406–414, <https://doi.org/10.1177/026988119901300412>
- Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G., 2009, Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration, *BMJ*, 339(aug11 2), b2880–b2880, <https://doi.org/10.1136/bmj.b2880>
- Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., & Haukka, J., 2006, Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort, *ARCH GEN PSYCHIATRY*, Volume 63, 1358-1367.
- Trangle M., Dieperink B., Gabert T., Haight B., Lindvall B., Mitchell J., Novak H., Rich D., Rossmiller D., Setterlund L., Somers K. Institute for Clinical Systems Improvement, 2012, Major Depression in Adults in Primary Care. <http://bit.ly/Depr0512>.
- Trivedi, M. H., Marangell, L. B., & Shelton, R. C., 2006, Use of Treatment Algorithms for Depression. *J Clin Psychiatry*. Volume 67. 1458-1465

- Turkcapar M.H., Orsel S., Iscan E.N., Akdemir A., Kilic E.Z., 1998, Moclobemide and Sertraline in the Treatment of Melancholic and Nonmelancholic Major Depression: A Comparative Study, *Hum, Psychopharmacol. Clin*, Volume 13, 21-27.
- Vezmar, S., Miljkovic, B., Vucicevic, K., Timotijevic, I., Prostran, M., Todorovic, Z., & Pokrajac, M., 2009, Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. *Journal of Pharmacological Sciences*, 110(1), 98–104. <https://doi.org/10.1254/jphs.09013FP>
- Wagner, S., Wollschläger, D., Dreimüller, N., Engelmann, J., Herzog, D. P., Roll, S. C., Tadić, A., & Lieb, K., 2020, Effects of age on depressive symptomatology and response to antidepressant treatment in patients with major depressive disorder aged 18 to 65 years. *Comprehensive Psychiatry*, 99, 152170. <https://doi.org/10.1016/j.comppsy.2020.152170>
- Wang, G., Gislum, M., Filippov, G., & Montgomery, S., 2015, Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: A Randomized, Double-blind Study, *Current Medical Research and Opinion*, Volume 31(4), 11. <https://doi.org/10.1185/03007995.2015.1014028>
- Wang G., You X., Wang X., Xu X., Bai L., Xie J., Yao Z., Yi Q., Ma J., Wang J., Zhuo J., Hu C., 2018, Safety and Effectiveness of Escitalopram in a 8-week Open Study in Chinese Patients with Depression and Anxiety, *Neuropsychiatric Disease and Treatment*, Volume 14, 2087-2097. <http://dx.doi.org/10.2147/NDT.S164673>
- Winokur, A., & Demartinis, N., 2012, *The Effects of Antidepressants on Sleep*, *Psychiatric Times* Vol 29 No 6, Volume 29, Issue 6, <https://www.psychiatrictimes.com/view/effects-antidepressants-sleep>
- World Health Organization, 2020, *Depression*, World Health Organization, diakses pada <https://www.who.int/news-room/fact-sheets/detail/depression>
- Yevtushenko, V. Y., Belous, A. I., Yevtushenko, Y. G., Gusinin, S. E., Buzik, O., & Agibalova, T. V., 2007, Efficacy and Tolerability of Escitalopram Versus Citalopram in Major Depressive Disorder: A 6-Week, Multicenter, Prospective, Randomized, Double-Blind, Active-Controlled Study in Adult Outpatients, *Clinical Therapeutics*, 29(11), 14. <http://doi.org/10.1016/j.clinthera.2007.11.014>